Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Sponsors » Next-Generation Discovery Workflows » COVID-19 GWAS Leads to Immune Genes Linked to Severe Disease, Treatment Targets

COVID-19 GWAS Leads to Immune Genes Linked to Severe Disease, Treatment Targets

Dec 11, 2020
|
staff reporter

NEW YORK – A new genome-wide association study led by University of Edinburgh investigators suggests genes that contribute to antiviral and inflammatory functions of the immune system may mediate COVID-19 disease severity in individuals from the UK, offering an avenue for developing, testing, and tailoring treatment options.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Breathe It Out

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

The Next Batch

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Switch for the Second

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.

Science Reviews How Non-Genetic DNA Features Expand Utility of Liquid Biopsies, Presents Study of Enzymes in DNA Methylation

In Science this week: review discusses advances in liquid biopsies, and more.

May
05
Featured Webinar

Establishing a Pharmacogenomic Service for Routine Clinical Care

Sponsored by
Illumina

Adverse drug reactions (ADRs) are responsible for around 5 percent of hospital admissions and occur in 6 percent to 15 percent of hospital stays.

What's Popular?

In Microarrays & Multiplexing

  1. GWAS Uncovers Sex-Based Differences in Genetic Origins of Chronic Pain

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.